Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
"We feel strongly about undertaking important corporate actions that reflect the true value of our shareholders’ equity."
-
REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...
-
VERAXA Biotech announces further progress with lead BiTAC® T-cell engager (BiTAC-TCE) program, initiates cell line development with ATUM.
-
LONDON and BOSTON and BUDAPEST, Hungary, July 02, 2026 (GLOBE NEWSWIRE) -- Treos Bio, a clinical-stage biotechnology company developing off-the-shelf and personalized active cancer immunotherapies...
-
Bay Hematology Oncology and American Oncology Network Welcome Dr. Bill Gai
-
Liminatus Pharma Amends Definitive Merger Agreement with InnocsAI to Expand Oncology Cell Therapy Pipeline
-
Neutra Corp’s Subsidiary Neutra Life Sciences Executes New Women’s Health Joint Venture and Expands Trial Portfolio
-
Austin, TX, USA, June 29, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “Hematologic Malignancies Testing Market Size, Trends and Insights By Product...
-
Patient enrollment has been completed; all enrolled patients remain aliveData presented at the Nuclear Medicine and Neuro-Oncology (NMN) Society Annual Symposium Garching/Munich and Münster, Germany...
-
Siren Biotechnology awarded $8M in grant funding from the California Institute for Regenerative Medicine (CIRM) to support clinical development of SRN-101